Definitive Healthcare (NASDAQ:DH) Rating Lowered to “Hold” at Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Several other research analysts also recently issued reports on the stock. Stephens dropped their target price on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Friday. Barclays lowered their price objective on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a research report on Monday, December 8th. Morgan Stanley reiterated an “underperform” rating and set a $3.50 target price on shares of Definitive Healthcare in a research note on Thursday, December 18th. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Canaccord Genuity Group lowered their price target on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.52.

Definitive Healthcare Stock Performance

Shares of Definitive Healthcare stock opened at $1.28 on Friday. Definitive Healthcare has a 1 year low of $1.14 and a 1 year high of $4.70. The firm’s 50-day moving average is $2.18 and its 200 day moving average is $2.87. The stock has a market cap of $180.94 million, a price-to-earnings ratio of -1.02 and a beta of 1.66. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.64 and a quick ratio of 1.64.

Institutional Trading of Definitive Healthcare

Large investors have recently modified their holdings of the company. State of Alaska Department of Revenue increased its position in Definitive Healthcare by 109.3% during the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after acquiring an additional 5,970 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Definitive Healthcare during the 2nd quarter valued at about $32,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Definitive Healthcare during the 4th quarter valued at about $35,000. Savant Capital LLC purchased a new stake in shares of Definitive Healthcare during the 2nd quarter valued at about $45,000. Finally, SG Americas Securities LLC bought a new position in shares of Definitive Healthcare in the 4th quarter worth approximately $46,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare News Summary

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.